Adalvo is pleased to announce the successful DCP closure for Dimethyl Fumarate 120 and 240mg hard capsules, and several market authorizations have been granted already. This is an additional wave of DCP approvals, where we are extending market coverage of this product, together with our partners.
Dimethyl Fumarate is being developed in collaboration with one of our strategic partners and is indicated in the treatment of relapsing remitting multiple sclerosis. Our product has been developed based on the reference brand Tecfidera had global sales of approximately $ 2.7bn in 2021, according to IQVIA.
Adalvo is looking forward to being amongst the first wave of companies launching this high-value generic product.
We continue to make investments to broaden our generic landscape and enhance the value for our partners.